S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

NewLink Genetics Stock Price, Forecast & Analysis (NASDAQ:NLNK)

$1.53
-0.01 (-0.65 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
$1.50
Now: $1.53
$1.55
50-Day Range
$1.14
MA: $1.45
$1.82
52-Week Range
$1.13
Now: $1.53
$2.27
Volume111,653 shs
Average Volume395,513 shs
Market Capitalization$57.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NLNK
CUSIP65151110
Phone515-296-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.47 million
Book Value$3.09 per share

Profitability

Net Income$-53,600,000.00
Net Margins-6,587.56%

Miscellaneous

Employees55
Market Cap$57.09 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive NLNK News and Ratings via Email

Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.


NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) released its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.27). The biotechnology company earned $0.25 million during the quarter. NewLink Genetics had a negative net margin of 6,587.56% and a negative return on equity of 34.44%. View NewLink Genetics' Earnings History.

When is NewLink Genetics' next earnings date?

NewLink Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for NewLink Genetics.

What price target have analysts set for NLNK?

2 analysts have issued 12 month price objectives for NewLink Genetics' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate NewLink Genetics' share price to reach $4.00 in the next year. This suggests a possible upside of 161.4% from the stock's current price. View Analyst Price Targets for NewLink Genetics.

What is the consensus analysts' recommendation for NewLink Genetics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NewLink Genetics.

Has NewLink Genetics been receiving favorable news coverage?

Press coverage about NLNK stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NewLink Genetics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for NewLink Genetics.

Are investors shorting NewLink Genetics?

NewLink Genetics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,790,000 shares, an increase of 44.4% from the September 30th total of 1,240,000 shares. Based on an average daily trading volume, of 304,000 shares, the short-interest ratio is currently 5.9 days. Currently, 6.2% of the shares of the stock are sold short. View NewLink Genetics' Current Options Chain.

Who are some of NewLink Genetics' key competitors?

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Synergy Pharmaceuticals (SGYP), Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), SunPower (SPWR), Celldex Therapeutics (CLDX), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), FireEye (FEYE), Novavax (NVAX) and Opko Health (OPK).

Who are NewLink Genetics' key executives?

NewLink Genetics' management team includes the folowing people:
  • Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)
  • Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)
  • Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)
  • Mr. Brian Wiley, Chief Commercial Officer (Age 51)
  • Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64)

Who are NewLink Genetics' major shareholders?

NewLink Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tower Research Capital LLC TRC (0.09%) and Wedbush Securities Inc. (0.07%). Company insiders that own NewLink Genetics stock include Carl W Langren and Ernest Talarico III. View Institutional Ownership Trends for NewLink Genetics.

Which institutional investors are buying NewLink Genetics stock?

NLNK stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc. and Tower Research Capital LLC TRC . View Insider Buying and Selling for NewLink Genetics.

How do I buy shares of NewLink Genetics?

Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $1.53.

How big of a company is NewLink Genetics?

NewLink Genetics has a market capitalization of $57.09 million and generates $12.47 million in revenue each year. The biotechnology company earns $-53,600,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe.View Additional Information About NewLink Genetics.

What is NewLink Genetics' official website?

The official website for NewLink Genetics is http://www.newlinkgenetics.com/.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]


MarketBeat Community Rating for NewLink Genetics (NASDAQ NLNK)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  357 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  642
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Featured Article: What is a blue-chip stock?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel